Moxifloxacin in the Initial Therapy of Tuberculosis: A Randomized, Phase 2 Trial

BACKGROUND: New therapies are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that may have additive activity to existing antituberculosis agents. We conducted a Phase 2 clinical trial to determin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Conde, Marcus B., Efron, Anne, Loredo, Carla, Muzy De Souza, Gilvan R., Graça, Nadja P., Cezar, Michelle C., Ram, Malathi, Chaudhary, Mohammad A., Bishai, William R., Kritski, Afranio L., Chaisson, Richard E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2009
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2866651/
https://ncbi.nlm.nih.gov/pubmed/19345831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(09)60333-0
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge